Academy of Diagnostics & Laboratory Medicine - Scientific Short
Scientific Shorts are brought to you by the
Historically, THC testing has played a crucial role in clinical settings, serving various purposes such as assessing impairment, monitoring patients for substance abuse, and ensuring compliance with legal requirements. However, in states where recreational marijuana is legal, the landscape of THC testing has shifted (1). Changing attitudes towards cannabis have led to a decrease in emphasis on punitive measures related to THC, with a growing recognition of responsible consumption. This shift prompts a reevaluation of the necessity and relevance of THC testing in these regions.
Despite the changing legal landscape, the utility of THC testing within clinical settings remains relevant for specific purposes. Healthcare professionals may need to assess patients for impairment, potential substance abuse disorders, i.e. cannabis hyperemesis syndrome, or to ensure that medical treatments are not adversely affected by cannabis use. Careful consideration of the clinical utility of THC testing is essential to strike a balance between patient care and evolving societal norms.
As attitudes towards THC continue to evolve, there is a growing need to develop separate drug screening panels catering to the nuances of legalized marijuana. Is it time for the laboratory medicine community to consider creating distinct panels for drug testing, with and without THC, to allow for a more nuanced approach to substance screening? This approach not only aligns with the changing legal landscape but also ensures that healthcare practices adapt to the complexities introduced by the legalization of marijuana.
Furthermore, even in states where THC remains illegal, variants such as delta-8 and delta-10 THC may still be permissible since the enactment of the 2018 Farm Bill (2). These legal nuances pose challenges for traditional THC testing methodologies, as they may not adequately distinguish between different THC forms. Healthcare professionals and testing facilities must navigate this intricate landscape to ensure accurate assessments and compliant practices. This underscores the need for updated testing protocols that consider the specific legal frameworks surrounding various THC derivatives. Staying abreast of evolving regulations is crucial to maintaining the integrity and relevance of THC testing in clinical settings.
Scientific Shorts are brought to you by the
Fellows of the Academy use the designation of FADLM. This designation is equivalent to FACB and FAACC, the previous designations used by fellows of the National Academy of Clinical Biochemistry and AACC Academy. Those groups were rebranded as Academy of Diagnostics & Laboratory Medicine in 2023.
